Institute of Immunology, Medical Faculty Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany.
Anal Biochem. 2012 Apr 15;423(2):261-8. doi: 10.1016/j.ab.2011.12.042. Epub 2012 Jan 4.
There is growing interest in the development of novel single-chain bispecific antibodies for retargeting of immune effector T cells to tumor cells. Until today, functional fusion constructs consisting of a single-chain bispecific antibody and a fluorescent protein were not reported. Such molecules could be useful for an in vivo visualization of this retargeting process. Recently, we established two novel single-chain bispecific antibodies. One is capable of retargeting T cells to CD33, and the other is capable of retargeting T cells to the prostate stem cell antigen (PSCA). CD33 is an attractive immunotarget on the surface of tumor cells from patients with acute myeloid leukemia (AML). The PSCA is a potential target on prostate cancer cells. Flanking the reading frame encoding the green fluorescent protein (GFP) with a recently described novel helical linker element allowed us to establish novel single-chain bispecific fusion antibodies. These fluorescent fusion antibodies were useful to efficiently retarget T cells to the respective tumor cells and visualize the formation of immune synapses between effector and target cells.
人们对开发新型单链双特异性抗体以将免疫效应 T 细胞重新靶向肿瘤细胞越来越感兴趣。直到今天,还没有报道过由单链双特异性抗体和荧光蛋白组成的功能性融合构建体。这种分子对于体内可视化这种重定向过程可能很有用。最近,我们建立了两种新型的单链双特异性抗体。一种能够将 T 细胞重新靶向 CD33,另一种能够将 T 细胞重新靶向前列腺干细胞抗原(PSCA)。CD33 是急性髓细胞白血病(AML)患者肿瘤细胞表面的一个有吸引力的免疫靶点。PSCA 是前列腺癌细胞的一个潜在靶点。用最近描述的新型螺旋连接子元件将编码绿色荧光蛋白(GFP)的阅读框排成一行,使我们能够建立新型的单链双特异性融合抗体。这些荧光融合抗体可有效地将 T 细胞重新靶向各自的肿瘤细胞,并可视化效应细胞和靶细胞之间免疫突触的形成。